431 related articles for article (PubMed ID: 28210207)
1. Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target.
Cassano T; Calcagnini S; Pace L; De Marco F; Romano A; Gaetani S
Front Neurosci; 2017; 11():30. PubMed ID: 28210207
[TBL] [Abstract][Full Text] [Related]
2. The influence of cannabinoids on generic traits of neurodegeneration.
Fagan SG; Campbell VA
Br J Pharmacol; 2014 Mar; 171(6):1347-60. PubMed ID: 24172185
[TBL] [Abstract][Full Text] [Related]
3. Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders.
Navarro G; Morales P; Rodríguez-Cueto C; Fernández-Ruiz J; Jagerovic N; Franco R
Front Neurosci; 2016; 10():406. PubMed ID: 27679556
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoid CB2 Receptors in Neurodegenerative Proteinopathies: New Insights and Therapeutic Potential.
Vuic B; Milos T; Tudor L; Konjevod M; Nikolac Perkovic M; Jazvinscak Jembrek M; Nedic Erjavec G; Svob Strac D
Biomedicines; 2022 Nov; 10(12):. PubMed ID: 36551756
[TBL] [Abstract][Full Text] [Related]
5. Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system.
Aymerich MS; Aso E; Abellanas MA; Tolon RM; Ramos JA; Ferrer I; Romero J; Fernández-Ruiz J
Biochem Pharmacol; 2018 Nov; 157():67-84. PubMed ID: 30121249
[TBL] [Abstract][Full Text] [Related]
6. Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others.
Fernández-Ruiz J; Romero J; Ramos JA
Handb Exp Pharmacol; 2015; 231():233-59. PubMed ID: 26408163
[TBL] [Abstract][Full Text] [Related]
7. Endocannabinoid Modulation in Neurodegenerative Diseases: In Pursuit of Certainty.
Vasincu A; Rusu RN; Ababei DC; Larion M; Bild W; Stanciu GD; Solcan C; Bild V
Biology (Basel); 2022 Mar; 11(3):. PubMed ID: 35336814
[TBL] [Abstract][Full Text] [Related]
8. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.
Palazuelos J; Aguado T; Pazos MR; Julien B; Carrasco C; Resel E; Sagredo O; Benito C; Romero J; Azcoitia I; Fernández-Ruiz J; Guzmán M; Galve-Roperh I
Brain; 2009 Nov; 132(Pt 11):3152-64. PubMed ID: 19805493
[TBL] [Abstract][Full Text] [Related]
9. Differential upregulation of the cannabinoid CB₂ receptor in neurotoxic and inflammation-driven rat models of Parkinson's disease.
Concannon RM; Okine BN; Finn DP; Dowd E
Exp Neurol; 2015 Jul; 269():133-41. PubMed ID: 25895887
[TBL] [Abstract][Full Text] [Related]
10. Endocannabinoid System in Neurological Disorders.
Ranieri R; Laezza C; Bifulco M; Marasco D; Malfitano AM
Recent Pat CNS Drug Discov; 2016; 10(2):90-112. PubMed ID: 27364363
[TBL] [Abstract][Full Text] [Related]
11. Neuropeptide Y (NPY) as a therapeutic target for neurodegenerative diseases.
Duarte-Neves J; Pereira de Almeida L; Cavadas C
Neurobiol Dis; 2016 Nov; 95():210-24. PubMed ID: 27461050
[TBL] [Abstract][Full Text] [Related]
12. Mast Cells in Neurodegenerative Disease.
Jones MK; Nair A; Gupta M
Front Cell Neurosci; 2019; 13():171. PubMed ID: 31133804
[TBL] [Abstract][Full Text] [Related]
13. Research progress on the cannabinoid type-2 receptor and Parkinson's disease.
Yu X; Jia Y; Dong Y
Front Aging Neurosci; 2023; 15():1298166. PubMed ID: 38264546
[TBL] [Abstract][Full Text] [Related]
14. Role of CB2 receptors in neuroprotective effects of cannabinoids.
Fernández-Ruiz J; Pazos MR; García-Arencibia M; Sagredo O; Ramos JA
Mol Cell Endocrinol; 2008 Apr; 286(1-2 Suppl 1):S91-6. PubMed ID: 18291574
[TBL] [Abstract][Full Text] [Related]
15. Type-2 cannabinoid receptors in neurodegeneration.
Bisogno T; Oddi S; Piccoli A; Fazio D; Maccarrone M
Pharmacol Res; 2016 Sep; 111():721-730. PubMed ID: 27450295
[TBL] [Abstract][Full Text] [Related]
16. Endocannabinoids and neurodegenerative diseases.
Micale V; Mazzola C; Drago F
Pharmacol Res; 2007 Nov; 56(5):382-92. PubMed ID: 17950616
[TBL] [Abstract][Full Text] [Related]
17. Cannabinoid Receptor 2-Deficiency Ameliorates Disease Symptoms in a Mouse Model with Alzheimer's Disease-Like Pathology.
Schmöle AC; Lundt R; Toporowski G; Hansen JN; Beins E; Halle A; Zimmer A
J Alzheimers Dis; 2018; 64(2):379-392. PubMed ID: 29865078
[TBL] [Abstract][Full Text] [Related]
18. Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB
Navarro G; Borroto-Escuela D; Angelats E; Etayo Í; Reyes-Resina I; Pulido-Salgado M; Rodríguez-Pérez AI; Canela EI; Saura J; Lanciego JL; Labandeira-García JL; Saura CA; Fuxe K; Franco R
Brain Behav Immun; 2018 Jan; 67():139-151. PubMed ID: 28843453
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of cannabinoid signaling in microglia by adenosine A
Franco R; Reyes-Resina I; Aguinaga D; Lillo A; Jiménez J; Raïch I; Borroto-Escuela DO; Ferreiro-Vera C; Canela EI; Sánchez de Medina V; Del Ser-Badia A; Fuxe K; Saura CA; Navarro G
Glia; 2019 Dec; 67(12):2410-2423. PubMed ID: 31429130
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoid Type 2 (CB2) Receptors Activation Protects against Oxidative Stress and Neuroinflammation Associated Dopaminergic Neurodegeneration in Rotenone Model of Parkinson's Disease.
Javed H; Azimullah S; Haque ME; Ojha SK
Front Neurosci; 2016; 10():321. PubMed ID: 27531971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
